Comparison between succinate dehydrogenase inhibition test and subrenal capsule assay for chemosensitivity testing

H. Anai, Yoshihiko Maehara, H. Kusumoto, K. Sugimachi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The chemosensitivity result of the succinate dehydrogenase inhibition (SDI) test was compared with that of the subrenal capsule (SRC) assay in 23 human tumor tissues exposed to adriamycin (ADM), mitomycin C (MMC), cisplatin (DDP) and 5-fluorouracil (5-FU). The chemosensitivity was considered as positive when the succinate dehydrogenase (SD) activity of the drug-exposed cells was decreased to below 50% of that of control cells on day 3 in the SDI test, and the tumor size on day 6 was decreased to below -10% of that on day 0 in the SRC assay. Correlation rates between the decrease of SD activity in the SDI test and the decrease of tumor size in the SRC assay, using 23 evaluable cases in both assays, were r = 0.717 for ADM, r = 0.699 for MMC, r = 0.796 for DDP and r = 0.735 for 5-FU. The correlations of the chemosensitivity results were 73.9% for ADM, 73.9% for MMC, 82.6% for DDP and 60.9% for 5-FU. A positive correlation was noted between the in vitro and in vivo chemosensitivity results. This SDI test can serve as an effective tool for chemosensitivity testing.

Original languageEnglish
Pages (from-to)115-117
Number of pages3
JournalOncology
Volume44
Issue number2
DOIs
Publication statusPublished - Jan 1 1987

Fingerprint

Subrenal Capsule Assay
Succinate Dehydrogenase
Mitomycin
Fluorouracil
Doxorubicin
Neoplasms
Cisplatin

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Comparison between succinate dehydrogenase inhibition test and subrenal capsule assay for chemosensitivity testing. / Anai, H.; Maehara, Yoshihiko; Kusumoto, H.; Sugimachi, K.

In: Oncology, Vol. 44, No. 2, 01.01.1987, p. 115-117.

Research output: Contribution to journalArticle

Anai, H. ; Maehara, Yoshihiko ; Kusumoto, H. ; Sugimachi, K. / Comparison between succinate dehydrogenase inhibition test and subrenal capsule assay for chemosensitivity testing. In: Oncology. 1987 ; Vol. 44, No. 2. pp. 115-117.
@article{6c0c4bf5ee0148c3b8ff9f5afbb11a51,
title = "Comparison between succinate dehydrogenase inhibition test and subrenal capsule assay for chemosensitivity testing",
abstract = "The chemosensitivity result of the succinate dehydrogenase inhibition (SDI) test was compared with that of the subrenal capsule (SRC) assay in 23 human tumor tissues exposed to adriamycin (ADM), mitomycin C (MMC), cisplatin (DDP) and 5-fluorouracil (5-FU). The chemosensitivity was considered as positive when the succinate dehydrogenase (SD) activity of the drug-exposed cells was decreased to below 50{\%} of that of control cells on day 3 in the SDI test, and the tumor size on day 6 was decreased to below -10{\%} of that on day 0 in the SRC assay. Correlation rates between the decrease of SD activity in the SDI test and the decrease of tumor size in the SRC assay, using 23 evaluable cases in both assays, were r = 0.717 for ADM, r = 0.699 for MMC, r = 0.796 for DDP and r = 0.735 for 5-FU. The correlations of the chemosensitivity results were 73.9{\%} for ADM, 73.9{\%} for MMC, 82.6{\%} for DDP and 60.9{\%} for 5-FU. A positive correlation was noted between the in vitro and in vivo chemosensitivity results. This SDI test can serve as an effective tool for chemosensitivity testing.",
author = "H. Anai and Yoshihiko Maehara and H. Kusumoto and K. Sugimachi",
year = "1987",
month = "1",
day = "1",
doi = "10.1159/000226457",
language = "English",
volume = "44",
pages = "115--117",
journal = "Oncology",
issn = "0030-2414",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Comparison between succinate dehydrogenase inhibition test and subrenal capsule assay for chemosensitivity testing

AU - Anai, H.

AU - Maehara, Yoshihiko

AU - Kusumoto, H.

AU - Sugimachi, K.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - The chemosensitivity result of the succinate dehydrogenase inhibition (SDI) test was compared with that of the subrenal capsule (SRC) assay in 23 human tumor tissues exposed to adriamycin (ADM), mitomycin C (MMC), cisplatin (DDP) and 5-fluorouracil (5-FU). The chemosensitivity was considered as positive when the succinate dehydrogenase (SD) activity of the drug-exposed cells was decreased to below 50% of that of control cells on day 3 in the SDI test, and the tumor size on day 6 was decreased to below -10% of that on day 0 in the SRC assay. Correlation rates between the decrease of SD activity in the SDI test and the decrease of tumor size in the SRC assay, using 23 evaluable cases in both assays, were r = 0.717 for ADM, r = 0.699 for MMC, r = 0.796 for DDP and r = 0.735 for 5-FU. The correlations of the chemosensitivity results were 73.9% for ADM, 73.9% for MMC, 82.6% for DDP and 60.9% for 5-FU. A positive correlation was noted between the in vitro and in vivo chemosensitivity results. This SDI test can serve as an effective tool for chemosensitivity testing.

AB - The chemosensitivity result of the succinate dehydrogenase inhibition (SDI) test was compared with that of the subrenal capsule (SRC) assay in 23 human tumor tissues exposed to adriamycin (ADM), mitomycin C (MMC), cisplatin (DDP) and 5-fluorouracil (5-FU). The chemosensitivity was considered as positive when the succinate dehydrogenase (SD) activity of the drug-exposed cells was decreased to below 50% of that of control cells on day 3 in the SDI test, and the tumor size on day 6 was decreased to below -10% of that on day 0 in the SRC assay. Correlation rates between the decrease of SD activity in the SDI test and the decrease of tumor size in the SRC assay, using 23 evaluable cases in both assays, were r = 0.717 for ADM, r = 0.699 for MMC, r = 0.796 for DDP and r = 0.735 for 5-FU. The correlations of the chemosensitivity results were 73.9% for ADM, 73.9% for MMC, 82.6% for DDP and 60.9% for 5-FU. A positive correlation was noted between the in vitro and in vivo chemosensitivity results. This SDI test can serve as an effective tool for chemosensitivity testing.

UR - http://www.scopus.com/inward/record.url?scp=0023265422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023265422&partnerID=8YFLogxK

U2 - 10.1159/000226457

DO - 10.1159/000226457

M3 - Article

C2 - 3574851

AN - SCOPUS:0023265422

VL - 44

SP - 115

EP - 117

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 2

ER -